Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "disease"

3230 News Found

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
Clinical Trials | January 20, 2026

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial

Improvements were also seen in complete response rates, duration of response, and time to next treatment


AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder
Biotech | January 20, 2026

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector


Syngene locks in Bristol Myers Squibb alliance through 2035
News | January 20, 2026

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle


Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early
News | January 20, 2026

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,


Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future
News | January 20, 2026

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development


EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
News | January 17, 2026

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike


Boston Scientific to acquire Penumbra in $14.5 billion deal
News | January 17, 2026

Boston Scientific to acquire Penumbra in $14.5 billion deal

Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion


Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
News | January 17, 2026

Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk

The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk


Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
News | January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination